Xu Ting, Tian Yin, Wang Yi, Yi Zhongmei, Li Chenchen, Wang Shichun, Fan Yahan, Yao Chunyan, Peng Guiyong, Lu Hua
Department of Blood Transfusion, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Department of Gastroenterology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Gastroenterol Res Pract. 2022 Jul 15;2022:7944849. doi: 10.1155/2022/7944849. eCollection 2022.
Peptic ulcer is a multifactorial and complex disease and affects a wide range of people worldwide. We provided a novel therapeutic approach for peptic ulcer and observed its effect.
Peptic ulcer patients were enrolled from 2016 to 2017 in Chongqing and randomly assigned to two groups: a control group that used only rabeprazole and a platelet-rich plasma (PRP) group that received a combination therapy of autologous PRP (aPRP) and rabeprazole. The therapeutic effect was assessed via the ulcer size and symptom score.
A total of 27 patients were included (12 patients in the control group and 15 patients in the PRP group) in this study. Our results showed that all participants have healed in 30 days, and there was no significant difference in healing time between the PRP group and the control group in different independent variables. However, regression analysis revealed that the healing time was 6.99 days shorter in the PRP group than that in the control group, and patients with higher symptom scores in the initial examination need more time to heal during treatment. Endoscopic results showed that the repaired ulcer in the PRP group was more similar to the normal gastric mucosa tissue than that the control group.
This study showed an encouraging preliminary result that aPRP has a positive result in patients with peptic ulcer and seems to be a better choice for refractory peptic ulcer treatment. Although further follow-up studies are needed to determine the duration of efficacy of aPRP, the approach will be helpful in improving the clinical treatment of peptic ulcer.
消化性溃疡是一种多因素的复杂疾病，影响着全球广泛人群。我们提供了一种针对消化性溃疡的新型治疗方法并观察其效果。
2016年至2017年在重庆招募消化性溃疡患者，随机分为两组：仅使用雷贝拉唑的对照组和接受自体富血小板血浆（aPRP）与雷贝拉唑联合治疗的富血小板血浆（PRP）组。通过溃疡大小和症状评分评估治疗效果。
本研究共纳入27例患者（对照组12例，PRP组15例）。我们的结果显示，所有参与者在30天内均已愈合，PRP组和对照组在不同自变量下的愈合时间无显著差异。然而，回归分析显示，PRP组的愈合时间比对照组短6.99天，初始检查时症状评分较高的患者在治疗期间需要更长时间愈合。内镜检查结果显示，PRP组修复后的溃疡比对照组更接近正常胃黏膜组织。
本研究显示了一个令人鼓舞的初步结果，即aPRP对消化性溃疡患者有积极效果，似乎是难治性消化性溃疡治疗的更好选择。尽管需要进一步的随访研究来确定aPRP的疗效持续时间，但该方法将有助于改善消化性溃疡的临床治疗。
